Short Interest Don’t Lie: Charles Riv Labs International Incorporated (NYSE:CRL)’s Stock Is Buy After Less Market Selling

November 30, 2016 - By Hazel Jackson   ·   0 Comments

Short Interest Don't Lie: Charles Riv Labs International Incorporated (NYSE:CRL)'s Stock Is Buy After Less Market Selling

The stock of Charles Riv Labs International Incorporated (NYSE:CRL) registered a decrease of 4.84% in short interest. CRL’s total short interest was 1.47M shares in November as published by FINRA. Its down 4.84% from 1.55 million shares, reported previously. With 354,100 shares average volume, it will take short sellers 4 days to cover their CRL’s short positions. The short interest to Charles Riv Labs International Incorporated’s float is 3.16%. About 183,530 shares traded hands. Charles River Laboratories Intl. Inc (NYSE:CRL) has declined 12.23% since April 27, 2016 and is downtrending. It has underperformed by 17.46% the S&P500.

Charles River Laboratories International, Inc. is a full service, early-stage contract research company. The company has a market cap of $3.42 billion. The Firm is engaged in the business of providing the research models required in research and development of new drugs, devices and therapies. It has a 24.24 P/E ratio. The Firm operates through three divisions: Research Models and Services , which consists of Research Models and Research Model Services; Discovery and Safety Assessment (DSA), which offers discovery and safety assessment services, both regulated and non-regulated, in which it includes both in vivo and in vitro studies, and Manufacturing Support (Manufacturing), which includes Microbial Solutions, Biologics Testing Solutions and Avian Vaccine Services.

Insitutional Activity: The institutional sentiment decreased to 0.95 in Q2 2016. Its down 0.48, from 1.43 in 2016Q1. The ratio dived, as 25 funds sold all Charles River Laboratories Intl. Inc shares owned while 81 reduced positions. 39 funds bought stakes while 113 increased positions. They now own 44.08 million shares or 4.37% less from 46.09 million shares in 2016Q1.
Ameritas Inv Prtnrs has invested 0.04% of its portfolio in Charles River Laboratories Intl. Inc (NYSE:CRL). Blackrock, a New York-based fund reported 45,553 shares. Wesbanco Retail Bank Incorporated accumulated 6,102 shares or 0.03% of the stock. Wedge Capital Management L Lp Nc holds 0.01% of its portfolio in Charles River Laboratories Intl. Inc (NYSE:CRL) for 9,533 shares. Bancorp Of Montreal Can has 0% invested in the company for 6,476 shares. Moreover, Foundry Prtnrs Ltd has 0.26% invested in Charles River Laboratories Intl. Inc (NYSE:CRL) for 55,694 shares. Tudor Investment Et Al accumulated 0.28% or 162,837 shares. Profund Advsr Lc holds 0.12% of its portfolio in Charles River Laboratories Intl. Inc (NYSE:CRL) for 30,239 shares. State Board Of Administration Of Florida Retirement accumulated 79,486 shares or 0.02% of the stock. Oak Limited Oh accumulated 0.33% or 32,900 shares. Price T Rowe Assoc Inc Md has 285,314 shares for 0% of their US portfolio. Oakbrook Ltd Limited Liability Company last reported 4,892 shares in the company. Bank Of Ny Mellon owns 956,960 shares or 0.02% of their US portfolio. Ahl Prtn Llp accumulated 7,307 shares or 0.03% of the stock. Calvert Invest Management last reported 2,703 shares in the company.

Insider Transactions: Since July 1, 2016, the stock had 0 buys, and 7 insider sales for $4.75 million net activity. $1.57M worth of shares were sold by FOSTER JAMES C on Friday, August 5. Another trade for 4,539 shares valued at $326,485 was sold by REESE C RICHARD. The insider MASSARO GEORGE sold 3,740 shares worth $310,750. $681,120 worth of Charles River Laboratories Intl. Inc (NYSE:CRL) was sold by WALLMAN RICHARD F on Friday, July 29. $662,446 worth of shares were sold by Molho Davide on Tuesday, August 30.

Charles River Laboratories Intl. Inc (NYSE:CRL) Ratings Coverage

Out of 10 analysts covering Charles River Laboratories (NYSE:CRL), 4 rate it a “Buy”, 3 “Sell”, while 3 “Hold”. This means 40% are positive. Charles River Laboratories has been the topic of 18 analyst reports since August 3, 2015 according to StockzIntelligence Inc. Credit Suisse initiated the stock with “Neutral” rating in Tuesday, June 21 report. The stock of Charles River Laboratories Intl. Inc (NYSE:CRL) has “Market Perform” rating given on Monday, October 12 by Wells Fargo. The rating was maintained by Barclays Capital with “Underweight” on Friday, May 20. The stock has “Buy” rating given by Gabelli on Tuesday, April 26. Citigroup maintained it with “Neutral” rating and $90 target price in Thursday, August 4 report. The rating was maintained by William Blair with “Outperform” on Friday, August 28. The stock of Charles River Laboratories Intl. Inc (NYSE:CRL) earned “Sell” rating by UBS on Tuesday, September 6. The stock has “Outperform” rating given by Robert W. Baird on Friday, January 8. As per Friday, August 14, the company rating was reinitiated by Credit Suisse. The stock has “Buy” rating given by Jefferies on Friday, January 8.

CRL Company Profile

Charles River Laboratories International, Inc., incorporated on February 3, 1994, is a full service, early-stage contract research company. The Firm is engaged in the business of providing the research models required in research and development of new drugs, devices and therapies. The Firm operates through three divisions: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). It develops a portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, which is able to support its clients from target identification through preclinical development. It also provides a suite of services and products to support its clients’ manufacturing activities.

More news for Charles River Laboratories Intl. Inc (NYSE:CRL) were recently published by: Benzinga.com, which released: “Benzinga’s Top Upgrades” on November 30, 2016. Barrons.com‘s article titled: “Micron Tech Insiders Sell $5.7 Million in Stock” and published on October 08, 2014 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Hazel Jackson


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>